Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Acalabrutinib plus venetoclax and rituximab in patients with treatment-naive (TN) mantle cell lymphoma (MCL): Results from the Phase 2 TrAVeRse study

View Full Paper
Ask AI
Bookmark
Share

Authors

WJWojciech JurczakACAbel CostaAWAdam Witkowski

Discussion

Loading...

Member takes

Overview

Phase 2 trial shows high complete response rates in treatment-naive mantle cell lymphoma, suggesting promising efficacy of acalabrutinib-based combination therapy.

Key Points

  • Overall response rate was 95.4% with 53.7% achieving complete response at the end of AVR induction.
  • Study involved patients with treatment-naive mantle cell lymphoma at multiple centers, highlighting the broad applicability of findings.
  • Adverse events included diarrhea and neutropenia, occurring significantly but manageable among participants.
  • Results emphasize the need for further investigation into acalabrutinib and combination therapies in patients with mantle cell lymphoma.

Cite This Study

Jurczak et al. (2025) studied this question.

synapsesocial.com/papers/69362f514fa91c937236d945https://doi.org/10.1182/blood-2025-884
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Phase I/II study of acalabrutinib, venetoclax, and obinutuzumab in patients with relapsed/refractory and previously untreated Mantle Cell Lymphoma (MAVO)2025 · 8 citations
  2. 2Mutation-guided finite-duration acalabrutinib plus venetoclax for relapse after first-line finite-duration COVALENT Bruton tyrosine kinase inhibitor plus venetoclax‒based combination therapy in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma: Phase 2 MAVRiC study2025
  3. 3Acalabrutinib plus rituximab followed by brexucabtagene autoleucel for frontline treatment of high-risk Mantle Cell Lymphoma: The window-3 clinical trial2025
  4. 4Time to third-line treatment after bendamustine-rituximab with or without acalabrutinib in patients with previously untreated mantle cell lymphoma: Updated analysis of the phase 3 ECHO trial after 50 months of follow-up2025
  5. 5Preliminary safety and efficacy of boven (Zanubrutinib, Obinutuzumab, and Venetoclax) as frontline therapy for older patients with Mantle Cell Lymphoma2025 · 4 citations